Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia.

Spadea, A; Petti, M C; Fazi, P; Vegna, M L; Arcese, W; Avvisati, G; Aloe Spiriti, M A; Latagliata, R; Meloni, G; Testi, A M

Spadea, A; Petti, M C; Fazi, P; Vegna, M L; Arcese, W; Avvisati, G; Aloe Spiriti, M A; Latagliata, R; Meloni, G; Testi, A M.

Affiliation

Spadea A; Department of Human Biopathology, University La Sapienza, Rome, Italy.

Leukemia ; 7(4): 549-52, 1993 Apr.

Article in En | MEDLINE | ID: mdl-8464233

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Child; Child, Preschool; Cisplatin/administration & dosage; Drug Administration Schedule; Etoposide/administration & dosage; Female; Humans; Male; Middle Aged; Mitoxantrone/administration & dosage; Risk; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols Type of study: Etiology_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 1993 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links